The remarkable clinical activity of chimeric antigen receptor (CAR) therapies in B cell and
plasma cell malignancies has validated the use of this therapeutic class for liquid cancers …

Dying mammalian cells emit numerous signals that interact with the host to dictate the
immunological correlates of cellular stress and death. In the absence of reactive antigenic …

Cancer immunology and immunotherapy are driving forces of research and development in
oncology, mostly focusing on CD8+ T cells and the tumor microenvironment. Recent …

Engineering a patient's own T cells to selectively target and eliminate tumour cells has cured
patients with untreatable haematologic cancers. These results have energized the field to …

T cells are crucial for immune functions to maintain health and prevent disease. T cell
development occurs in a stepwise process in the thymus and mainly generates CD4+ and …

Regulatory T (Treg) cells, although vital for immune homeostasis, also represent a major
barrier to anti-cancer immunity, as the tumour microenvironment (TME) promotes the …

The steadfast advance of the synthetic biology field has enabled scientists to use genetically
engineered cells, instead of small molecules or biologics, as the basis for the development …

Recent advances in machine learning and experimental biology have offered breakthrough
solutions to problems such as protein structure prediction that were long thought to be …

Background & Aims Regulatory T-cells (Tregs) impair cancer immunosurveillance by
creating an immunosuppressive environment that fosters tumor cell survival. Our previous …

Immune-checkpoint blockade (ICB) promotes antitumor immune responses and can result in
durable patient benefit. However, response rates in breast cancer patients remain modest …